MAGE A3/A6 TCR

Drug Profile

MAGE A3/A6 TCR

Alternative Names: anti-MAGE A3/A6 TCR

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Cancer Institute (USA)
  • Class Cell therapies
  • Mechanism of Action Gene transference; MAGEA-3-protein-modulators; T lymphocyte replacements; T-cell receptor antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Solid tumours

Most Recent Events

  • 03 Oct 2017 Kite Pharma has been acquired by Gilead Sciences
  • 21 Mar 2016 Phase-II clinical trials for Solid tumours in USA (Kite Pharma pipeline; March 2016)
  • 29 Feb 2016 Kite Pharma plans to file an IND application with the US FDA for a TCR product candidate that targets a MAGE antigen expressed on Solid tumours (Kite Pharma 8-K; February 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top